BPC November 15 update

EyePoint EYPT Phase 1 data; Mesoblast MESO Phase 3 data

Pre-Market Updates

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) released data from its Phase 1 DAVIO trial of EYP-1901 to treat wet age-related macular degeneration (wet AMD). 76% and 53% of patients did not require rescue following a single dose up to 4 and 6 months, with stable and sustained BCVA (-2.5 letters) and CST (-2.7 μm).

Mesoblast Limited (NASDAQ: MESO) announced results from its Phase 3 trial of rexlemestrocel-L to treat chronic heart failure (CHF). Results reported that treatment with standard of care reduced the incidence of heart attacks or strokes by 65%, and in patients with high levels of inflammation, treatment reduced the incidence of heart attacks or strokes by 79%.

Biophytis SA (NASDAQ CM: BPTS) announced that patient recruitment has restarted, following a recommendation from the Data Monitoring Committee (DMC) and the FDA confirmation of protocol.

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) reported a new analysis of its Phase 3 trials SOLOIST and SCORED of sotagliflozin to treat heart failure. Treatment consistently reduced total cardiovascular deaths, hospitalizations for heart failure, and urgent visits for heart failure across the full range of kidney function.

Goldman Sachs downgraded BioXcel Therapeutics (NASDAQ: BTAI) from Buy to Sell and lowered the price target from $55 to $24.

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) released new data from a post-hoc analysis of its Phase 3 NODE-301 trial of etripamil nasal spray to treat paroxysmal supraventricular tachycardia (PSVT). Etripamil significantly decreased heart rate (HR) before conversion to sinus rhythm (SR).

Pre-Market Advancers

CompanyPriceChange
PTN
Palatin Technologies Inc.
$0.79+0.2324  +41.68%
STSA
Satsuma Pharmaceuticals Inc.
$5.96+0.71  +13.52%
BYSI
BeyondSpring Inc.
$16.25+1.9  +13.24%
ACHL
Achilles Therapeutics plc
$5.39+0.55  +11.36%
OGEN
Oragenics Inc.
$0.60+0.0488  +8.87%
DRMA
Dermata Therapeutics Inc.
$2.93+0.23  +8.52%
UNCY
Unicycive Therapeutics Inc.
$3.16+0.24  +8.22%
WDNA
WisdomTree BioRevolution Fund
$26.00+1.8493  +7.66%
LOGC
LogicBio Therapeutics Inc.
$3.15+0.21  +7.14%
URGN
UroGen Pharma Ltd.
$13.00+0.86  +7.08%

Pre-Market Decliners

CompanyPriceChange
NAVB
Navidea Biopharmaceuticals Inc.
$1.15-0.15  -11.54%
IKT
Inhibikase Therapeutics Inc.
$1.91-0.15  -7.28%
PSTI
Pluristem Therapeutics Inc.
$2.52-0.17  -6.32%
BPTS
Biophytis SA
$5.40-0.36  -6.25%
APVO
Aptevo Therapeutics Inc.
$12.26-0.81  -6.20%
ANGN
Angion Biomedica Corp.
$3.54-0.2099  -5.60%
PBLA
Panbela Therapeutics Inc.
$1.86-0.11  -5.58%
VLON
Vallon Pharmaceuticals Inc.
$5.05-0.26  -4.90%
RVPH
Reviva Pharmaceuticals Holdings Inc.
$3.60-0.18  -4.76%
CRNX
Crinetics Pharmaceuticals Inc.
$23.25-1.15  -4.71%